Michael Cannon-Brookes's most recent trade in Moleculin Biotech Inc was a trade of 150,000 Stock Options (right to buy) done . Disclosure was reported to the exchange on Nov. 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Moleculin Biotech Inc | Michael D. Cannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2025 | 150,000 | 165,336 | - | - | Stock Options (right to buy) | |
| Lam Research | Michael R. Cannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2025 | 1,635 | 191,375 (0%) | 0% | 0 | Common Stock | |
| Seagate Tech | Michael R. Cannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Oct 2025 | 1,868 | 1,868 | - | - | Restricted Share Unit | |
| Seagate Tech | Michael R. Cannon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2025 | 3,427 | 0 | - | - | Restricted Share Unit | |
| Seagate Tech | Michael R. Cannon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2025 | 3,427 | 14,262 (0%) | 0% | 0 | Ordinary Shares | |
| Seagate Tech | Michael R. Cannon | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.40 per share. | 19 Oct 2025 | 823 | 13,439 (0%) | 0% | 225.4 | 185,504 | Ordinary Shares |
| Seagate Tech | Michael R. Cannon | Director | Sale of securities on an exchange or to another person at price $ 119.00 per share. | 02 Jun 2025 | 24,190 | 10,835 (0%) | 0% | 119.0 | 2,878,646 | Ordinary Shares |
| Lam Research | Michael R. Cannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2024 | 2,950 | 189,740 (0%) | 0% | 0 | Common Stock | |
| Moleculin Biotech Inc | Michael D. Cannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2024 | 10,000 | 15,336 | - | - | Stock option (right to buy) | |
| Seagate Tech | Michael R. Cannon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2024 | 5,436 | 35,025 (0%) | 0% | 0 | Ordinary Shares | |
| Seagate Tech | Michael R. Cannon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2024 | 5,436 | 0 | - | - | Restricted Share Unit | |
| Seagate Tech | Michael R. Cannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Oct 2024 | 3,427 | 3,427 | - | - | Restricted Share Unit | |
| Moleculin Biotech Inc | Michael D. Cannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 15,000 | 80,001 | - | - | Stock option (right to buy) | |
| Lam Research | Michael R. Cannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2022 | 563 | 18,310 (0%) | 0% | 0 | Common Stock | |
| Seagate Tech | Michael R. Cannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Oct 2022 | 4,840 | 4,840 | - | - | Restricted Share Unit | |
| Seagate Tech | Michael R. Cannon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Oct 2022 | 4,024 | 27,941 (0%) | 0% | 0 | Ordinary Shares | |
| Seagate Tech | Michael R. Cannon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Oct 2022 | 4,024 | 0 | - | - | Restricted Share Unit | |
| Seagate Tech | Michael R. Cannon | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.03 per share. | 20 Oct 2022 | 1,449 | 26,492 (0%) | 0% | 53.0 | 76,840 | Ordinary Shares |
| Moleculin Biotech Inc | Michael D. Cannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2022 | 23,333 | 50,001 | - | - | Stock option (right to buy) | |
| Moleculin Biotech Inc | Michael D. Cannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2022 | 15,000 | 65,001 | - | - | Stock option (right to buy) | |
| Lam Research | Michael R. Cannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2021 | 377 | 17,747 (0%) | 0% | 0 | Common Stock | |
| Seagate Tech | Michael R. Cannon | Director | Sale of securities on an exchange or to another person at price $ 97.48 per share. | 10 Jun 2021 | 7,102 | 20,175 (0%) | 0% | 97.5 | 692,269 | Ordinary Shares |
| Moleculin Biotech Inc | Michael D. Cannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 10,000 | 26,668 | - | - | Stock option (right to buy) |